Takeda receives FDA approval for EDARBI to treat hypertension in adults
Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals North America, Inc., today announced that the U.S. Food and Drug Administration approved EDARBI for the...
View ArticleMerck announces changes to high-dose simvastatin prescribing information in...
Merck, known as MSD outside the United States and Canada, today announced changes to the prescribing information in the United States for the highest dose of simvastatin, 80 mg, and the use of...
View ArticlePar Pharmaceutical reports second quarter total revenues of $224.2 million
Par Pharmaceutical Companies, Inc. today reported results for the second quarter ended June 30, 2011.
View ArticleMerck receives FDA approval for JUVISYNC to treat type 2 diabetes
Merck, known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved JUVISYNC(sitagliptin and simvastatin), a new treatment for type 2...
View ArticleFDA EMDAC votes to recommend approval of Merck's VYTORIN for pre-dialysis CKD
Merck, known as MSD outside the United States and Canada, announced today that the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) unanimously voted...
View ArticleRanbaxy introduces Atorvastatin-Amlodipine besylate tablets in the U.S.
Ranbaxy Pharmaceuticals Inc., a wholly owned subsidiary of Ranbaxy Laboratories Ltd., has launched an authorized generic version of Caduet in the U.S. market, as part of an agreement with Pfizer Inc.
View ArticleRanbaxy signs consent decree with U.S. FDA
Ranbaxy Laboratories Ltd. today announced that it has signed a consent decree with the U.S. Food and Drug Administration.
View ArticleWeight gain or loss may also depend on medicines taken
Weight gain or loss may not always be caused by what you eat or how much you exercise. For some, it's the medicines you're taking.
View ArticleNo added benefit of aliskiren-amlodipine fixed drug combination for hypertension
The fixed drug combination of aliskiren and amlodipine (trade name: Rasilamlo-) was approved in April 2011 for the treatment of people with hypertension in whom aliskiren or amlodipine alone has an...
View ArticleLatest polypill trial yields largest improvements yet
The results of the first trial to administer the polypill on the basis of age alone has shown the largest reductions in blood pressure and cholesterol level of any polypill trial to date, researchers...
View ArticleBMI may influence which blood pressure treatments work best
According to new research published Online First in The Lancet, body mass index (BMI) may influence which blood pressure medications work best at reducing the major complications of high blood pressure...
View ArticleDiuretic-based antihypertensive therapy touted for obese
Diuretic-based antihypertensive regimens may be preferable to calcium channel blocker-based therapy in patients who are obese, suggest researchers writing in The Lancet.
View ArticleStudy assesses relationship between BMI and CV events in hypertensive...
Low BMI is a risk factor for CVD in hypertensive patients with diabetes, according to research presented at the ESC Congress today by Dr Takanori Nagahiro from Japan. The findings provide evidence for...
View ArticleCalcium-channel blocker and antibiotic intake linked with small but greater...
Among older adults taking a calcium-channel blocker, simultaneous use of the antibiotic clarithromycin, compared with azithromycin, was associated with a small but statistically significant greater...
View ArticleFDA approves OLYSIO (simeprevir) for treatment of chronic hepatitis C infection
Janssen Therapeutics, Division of Janssen Products, LP, announced today the U.S. Food and Drug Administration has approved OLYSIO (simeprevir), an NS3/4A protease inhibitor, for the treatment of...
View ArticleDr. Reddy's Laboratories launches Amlodipine Besylate and Atorvastatin...
Dr. Reddy's Laboratories announced today that it has launched Amlodipine Besylate and Atorvastatin Calcium Tablets 2.5/10mg, 2.5/20mg, 2.5/40mg, 5/10mg, 5/20mg, 5/40mg, 5/80mg, 10/10mg, 10/20mg,...
View ArticleJanssen submits sNDA to FDA for simeprevir in combination with sofosbuvir for...
Janssen Research & Development, LLC (Janssen) today announced it has submitted a Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for simeprevir, an NS3/4A...
View ArticleFDA accepts Symplmed's Prestalia NDA for hypertension treatment
Symplmed announced today that the U.S. Food and Drug Administration has accepted for review its New Drug Application (NDA) for investigational drug Prestalia, the first single-pill, fixed-dose...
View ArticlePar Pharmaceutical starts shipping generic version of Exforge
Par Pharmaceutical Companies, Inc. today announced that it has begun shipping all four strengths of amlodipine and valsartan tablets, the generic version of Novartis' Exforge. Par received final...
View ArticleMylan announces U.S. launch of Amlodipine and Valsartan Tablets
Mylan N.V. today announced the U.S. launch of Amlodipine and Valsartan Tablets, 5 mg/160 mg, 5 mg/320 mg, 10 mg/160 mg, 10 mg/320 mg, which is the generic version of Novartis' Exforge Tablets.
View Article
